CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...